The primary objective of this research is to study the efficacy and safety of temporal interference stimulation for regulating the blood pressure.
Age: 18-65 years old, male or female;
Essential Hypertension Grade 1 (Low Risk) - Antihypertensive Medication-Naive Group: No other cardiovascular risk factors or disease history, with systolic blood pressure (SBP) ≥140 mmHg and <160 mmHg and/or diastolic blood pressure (DBP) ≥90 mmHg and <100 mmHg;
Essential Hypertension - Refractory Hypertension Group: Meeting one of the following conditions after intensive lifestyle intervention plus taking 3 different types of antihypertensive drugs (including thiazide diuretics) for ≥4 weeks, with each drug at the maximum dose or maximum tolerated dose: Clinic blood pressure ≥140/90 mmHg and 24-hour average ambulatory blood pressure ≥130/80 mmHg, or average home blood pressure ≥135/85 mmHg; or blood pressure can only be controlled below 140/90 mmHg with ≥4 types of antihypertensive drugs;
Neurogenic Orthostatic Hypotension (nOH) Group: A decrease in SBP ≥20 mmHg and/or DBP ≥10 mmHg within 3 minutes of the head-up tilt test (HUTT) and/or standing activity;
Patients with secondary hypertension;
Patients with intracranial structural lesions (e.g., infarcts, vascular malformations, space-occupying lesions, etc.);
Pregnant women;
Individuals unable to cooperate due to mental illness or other reasons;
Single group
Temporal Interference
Other interventionThe intervention will consist of 5 days of 20-min temporal interference stimulation.
Blood Pressure (BP24)
Blood Pressure (BP24) is defined as 24-hour ambulatory blood pressure monitoring in each 4 weeks.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
